Prompt initiation of durvalumab and tremelimumab treatment for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results